Ftse Mib
33.494,83
0,60%
DAX
19.322,59
0,91%
S&P 500
5.969,34
0,35%
NASDAQ
19.003,65
0,16%
Bitcoin
96.707,53
-1,10%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Flexion Therapeutics Inc (FLXN) Flexion Therapeutics Inc (FLXN) Notizie

FLXN

Flexion Therapeutics (FLXN)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:FLXN
DataOraFonteTitoloSimboloCompagnia
26/11/202112:07Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:FLXNFlexion Therapeutics Inc
24/11/202112:24Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:FLXNFlexion Therapeutics Inc
19/11/202116:21Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:FLXNFlexion Therapeutics Inc
19/11/202115:29Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:FLXNFlexion Therapeutics Inc
19/11/202115:27Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:FLXNFlexion Therapeutics Inc
19/11/202115:12Edgar (US Regulatory)Amended Statement of Ownership: Solicitation (sc 14d9/a)NASDAQ:FLXNFlexion Therapeutics Inc
19/11/202115:02Edgar (US Regulatory)Amended Tender Offer Statement by Third Party (sc To-t/a)NASDAQ:FLXNFlexion Therapeutics Inc
19/11/202114:40GlobeNewswire Inc.Pacira BioSciences Completes Acquisition of Flexion Therapeutics and Strengthens Leadership Position in Non-Opioid Pain ManagementNASDAQ:FLXNFlexion Therapeutics Inc
22/10/202112:49Edgar (US Regulatory)Statement of Ownership: Solicitation (sc 14d9)NASDAQ:FLXNFlexion Therapeutics Inc
22/10/202112:07Edgar (US Regulatory)Tender Offer Statement by Third Party (sc To-t)NASDAQ:FLXNFlexion Therapeutics Inc
12/10/202122:17Edgar (US Regulatory)Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c)NASDAQ:FLXNFlexion Therapeutics Inc
12/10/202112:08Edgar (US Regulatory)Written Communication Relating to an Issuer or Third Party (sc To-c)NASDAQ:FLXNFlexion Therapeutics Inc
11/10/202122:26PR Newswire (US)ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Flexion Therapeutics, Inc.NASDAQ:FLXNFlexion Therapeutics Inc
11/10/202113:00GlobeNewswire Inc.Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain ManagementNASDAQ:FLXNFlexion Therapeutics Inc
01/10/202122:30GlobeNewswire Inc.Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:FLXNFlexion Therapeutics Inc
08/09/202122:30GlobeNewswire Inc.Flexion Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceNASDAQ:FLXNFlexion Therapeutics Inc
03/09/202115:00GlobeNewswire Inc.Flexion Therapeutics to Present at the Wells Fargo 2021 Virtual Healthcare ConferenceNASDAQ:FLXNFlexion Therapeutics Inc
02/09/202113:30GlobeNewswire Inc.Flexion Therapeutics Announces Inclusion of ZILRETTA® in American Academy of Orthopaedic Surgeons (AAOS) Clinical Practice Guidelines for the Management of Osteoarthritis of the KneeNASDAQ:FLXNFlexion Therapeutics Inc
25/08/202113:30GlobeNewswire Inc.Flexion Therapeutics Announces Expansion of Phase 1b Trial Investigating FX301 for the Management of Post-Operative PainNASDAQ:FLXNFlexion Therapeutics Inc
09/08/202122:30GlobeNewswire Inc.Flexion Therapeutics Announces Publication of Results from Phase 2 Pharmacokinetics (PK) and Safety Study of ZILRETTA® in Shoulder Osteoarthritis (OA)NASDAQ:FLXNFlexion Therapeutics Inc
04/08/202122:10Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:FLXNFlexion Therapeutics Inc
04/08/202122:03Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:FLXNFlexion Therapeutics Inc
04/08/202122:01GlobeNewswire Inc.Flexion Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Business HighlightsNASDAQ:FLXNFlexion Therapeutics Inc
29/07/202122:15GlobeNewswire Inc.Flexion Therapeutics to Report Second-Quarter 2021 Financial Results on August 4, 2021NASDAQ:FLXNFlexion Therapeutics Inc
12/07/202122:30GlobeNewswire Inc.Flexion Therapeutics Announces Appointment of Utpal Koppikar to its Board of DirectorsNASDAQ:FLXNFlexion Therapeutics Inc
12/07/202122:04Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:FLXNFlexion Therapeutics Inc
02/07/202122:30GlobeNewswire Inc.Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:FLXNFlexion Therapeutics Inc
14/06/202122:30GlobeNewswire Inc.Flexion Therapeutics to Present at the 2021 Raymond James Human Health Innovation ConferenceNASDAQ:FLXNFlexion Therapeutics Inc
09/06/202122:15GlobeNewswire Inc.Flexion Therapeutics Announces Appointment of William T. Andrews, M.D., F.A.C.P., as Chief Medical OfficerNASDAQ:FLXNFlexion Therapeutics Inc
02/06/202122:30GlobeNewswire Inc.Flexion Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Virtual ConferenceNASDAQ:FLXNFlexion Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:FLXN

La tua Cronologia

LSE
86LY
Bpe Cap.4.93%nt
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network